No Data
Earnings Are Growing at Yabao Pharmaceutical Group (SHSE:600351) but Shareholders Still Don't Like Its Prospects
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Yabao Pharmaceutical Group (600351.SH): The injection solution of m-phenylenediamine has obtained the pharmaceutical registration certificate.
Yabao Pharmaceutical Group (600351.SH) announced that recently, the company received a notice from the National Medical Products Administration (referred to as "National...")
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yabao Pharmaceutical Group (600351.SH): ZY-A001 has received the clinical trial approval notification.
Yabao Pharmaceutical Group (600351.SH) issued an announcement, recently, the company received approval from the National Medical Products Administration...
The Market Doesn't Like What It Sees From Yabao Pharmaceutical Group Co., Ltd's (SHSE:600351) Earnings Yet As Shares Tumble 27%